PREVENTION OF LIVER CANCER--EAST ASIANS IN PHILADELPHIA

预防肝癌——费城的东亚人

• 批准号: 3185291
• 负责人: William Thomas LONDON
• 金额: $ 30.27万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-05-15 至 1992-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3185291
• 关键词: East Indian; alpha fetoprotein; cancer prevention; cancer risk; disease /disorder model; disease carrier state; ferritin; hepatitis A; hepatitis B virus group; hepatocellular carcinoma; human subject; monoclonal antibody; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology

Primary hepatocellular carcinoma (PHC) is one of the most common cancers in the world. Clinically identified tumors are uniformly lethal. However, a high-risk population for PHC has been defined, and a serological marker identified. At high risk are chronic carriers of hepatitis B virus (HBV), and rises in the serum alpha fetoprotein (AFP) levels indicate early PHC's. Such tumors are small and easily resectable; the patients have a good prognosis. Therefore, PHC presents a unique opportunity to develop a model cancer control research progress. This application details a cancer control program based on a two-step approach: 1) identification of the HBV carriers; and 2) monitoring the AFP levels of HBV carriers. Characteristic changes in AFP levels allow PHC's to be detected at an early, resectable stage. The objectives are: 1) To identify 5000 HBV carriers within the east Asian populations of the Philadelphia area. East Asian populations have high HBV carrier rates and are, therefore, the focus of the screening effort. 2) To detect 10 resectable PHC's per year among the monitored population. 3) To compare the survival of the resected patients with the survival of non-resected patients listed in the New Jersey and Pennsylvania tumor registries. 4) To evaluate screening tests for PHC other than AFP; specifically, serum ferritin levels, monoclonal antibodies to PHC ferritin and serum epoxide hydrolase. A Liver Cancer Prevention Center (LCPC) has been established at Fox Chase Cancer Center (FCCC). The HBV carriers will be identified through the Philadelphia Health Department clinics, church screenings, private physician referrals and testing at the LCPC. Carriers will be monitored at six-month intervals at the LCPC for AFP elevation. Persons with characteristic AFP elevations will undergo scanning and other diagnostic procedures for PHC. All treatment and follow-up will be carried out at the FCCC.

原发性肝细胞癌（PHC）是最常见的癌症之一 世界。 临床上发现的肿瘤都是致命的。 然而，一个 已经确定了 PHC 高危人群，并建立了血清学标志物 确定。 乙型肝炎病毒 (HBV) 慢性携带者处于高风险状态， 血清甲胎蛋白 (AFP) 水平的升高表明早期 初级卫生保健中心。 此类肿瘤较小且易于切除；患者有一个 预后良好。 因此，初级卫生保健提供了一个独特的机会来发展 模型癌症控制研究进展。 该申请详细介绍了基于两步的癌症控制计划 方法：1）乙型肝炎病毒携带者的鉴定； 2) 监控法新社 乙肝病毒携带者的水平。 AFP 水平的特征性变化允许 PHC 在早期、可切除阶段被发现。 目标是： 1) 在东亚人群中识别出 5000 名 HBV 携带者 费城地区。 东亚人群乙肝病毒携带率较高 因此，是筛查工作的重点。 2）检测10个 受监测人群中每年可切除的 PHC 数。 3）比较 切除患者的生存率与未切除患者的生存率 新泽西州和宾夕法尼亚州肿瘤登记处列出的患者。 4) 至 评估 AFP 以外的 PHC 筛查测试；具体来说，血清 铁蛋白水平、PHC 铁蛋白单克隆抗体和血清环氧化物 水解酶。 Fox Chase 设立肝癌预防中心 (LCPC) 癌症中心（FCCC）。 乙肝病毒携带者将通过 费城卫生局诊所、教堂筛查、私人 LCPC 的医生转诊和测试。 运营商将受到监控 LCPC 每隔六个月检测 AFP 升高。 患有以下疾病的人 特征性 AFP 升高将接受扫描和其他诊断 PHC 程序。 所有治疗和随访将在 FCCC。